|
[1] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med,2019, 380(15):1450-1462.
|
|
[2] RICH NE, HESTER C, ODEWOLE M, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2019, 17(3):551-559.
|
|
[3] LLOVET JM, MONTAL R, SIA D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10):599-616.
|
|
[4] SIM HW, KNOX J. Hepatocellular carcinoma in the era of immunotherapy[J]. Curr Probl Cancer, 2018, 42(1):40-48.
|
|
[5] CHOI JY, LEE JM, SIRLIN CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma:Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features[J]. Radiology, 2014, 273(1):30-50.
|
|
[6] ICHIKAWA T, SANO K, MORISAKA H. Diagnosis of pathologically early HCC with EOB-MRI:Experiences and current consensus[J]. Liver Cancer, 2014, 3(2):97-107.
|
|
[7] CHOU CT, CHOU JM, CHANG TA, et al. Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma:The utility of conventional MR imaging[J]. World J Gastroenterol, 2013, 19(42):7433-7439.
|
|
[8] MATSUI O, KOBAYASHI S, SANADA J, et al. Hepatocelluar nodules in liver cirrhosis:Hemodynamic evaluation(angiography-assisted CT)with special reference to multi-step hepatocarcinogenesis[J]. Abdom Imaging, 2011, 36(3):264-272.
|
|
[9] MARTENS P, NEVENS F. Budd-Chiari syndrome[J]. United European Gastroenterol J, 2015, 3(6):489-500.
|
|
[10] BANSAL V, GUPTA P, SINHA S, et al. Budd-Chiari syndrome:Imaging review[J]. Br J Radiol, 2018, 91(1092):20180441.
|
|
[11] EAPEN CE, VELISSARIS D, HEYDTMANN M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome[J]. Gut, 2006, 55(6):878-884.
|
|
[12] VALLA DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatol Int, 2018, 12(Suppl 1):168-180.
|
|
[13] CHANG XJ, LI YY, YANG B, et al. Association of biological characteristics of hepatitis B virus with the progression of liver fibrosis[J]. J Clin Hepatol, 2019, 35(8):1834-1837.(in Chinese）常秀娟，李因茵，杨斌，等．HBV生物学特性与肝纤维化进展的关系[J]．临床肝胆病杂志，2019, 35(8):1834-1837.
|
|
[14] CHEN YP. Advances in the diagnosis and treatment of noncirrhotic sinusoidal portal hypertension[J]. J Clin Hepatol,2019, 35(1):18-22.(in Chinese）陈永鹏．肝硬化以外窦性门静脉高压症的诊断与治疗[J]．临床肝胆病杂志，2019, 35(1):18-22.
|
DownLoad: